Health Condition 1: M049- Autoinflammatory syndrome, unspecified Health Condition 2: Q189- Congenital malformation of face and neck, unspecified Health Condition 3: M245- Contracture of joint Health Condition 4: R600- Localized edema Health Condition 5: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx Health Condition 6: M266- Temporomandibular joint disorders
Conditions
Interventions
Intervention1: Airway Nerve Block(superior laryngeal, transtracheal nerve block): Injection Lignocaine 2% (2ml)with Injection Glycopyrrolate (5mcg/kg) with 1% Lignocaine Jelly in both nostrils.
Contro
Sponsors
Pacific medical college and hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1 Adult patients aged between 18-60. 2 Patients belonging to American Society of Anesthesiologists grade I and II. 3 Anticipated difficult airway.
Exclusion criteria
Exclusion criteria: 1 Age less than 18 and more than 60. 2 ASA class 3 and above. 3 Patients allergic to lignocaine or any other study drug. 4 Epileptic patient. 5 Patients with hemodynamic instability. 6 Patients suffering from bronchial asthma. 7 Patients with decreased lung compliance. 8 Patients having deranged blood coagulation profile.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of lignocaine nebulisation and airway nerve block. Intubation time. Quality of airway anesthesia. Hemodynamic monitoring. Patient comfort score. Complications.Timepoint: 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient comfort score. Complication like cough spasm, lignocaine toxicity.Timepoint: 24 months | — |
Countries
India
Contacts
Public ContactHitanshu Sharma
Pacific medical college and hospital
Outcome results
None listed